eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects
10 nov. 2017 10h00 HE
|
EFFECTOR Therapeutics
SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster...
eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
04 oct. 2017 10h00 HE
|
EFFECTOR Therapeutics
SAN DIEGO, Oct. 04, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has...
Pet Cancer Therapeutics Market worth over $300 million by 2024: Global Market Insights, Inc.
09 août 2017 06h30 HE
|
Global Market Insights, Inc
Ocean View, Delaware, Aug. 09, 2017 (GLOBE NEWSWIRE) -- The Industry Analysis report “Pet Cancer Therapeutics Market By Medicine Type (Chemotherapy Drugs and Vaccines), By Species (Dogs and Cats),...
Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL)
15 mai 2017 06h22 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China
29 nov. 2016 07h16 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...
From Nurse to Patient
06 févr. 2014 17h44 HE
|
Genentech
MISSION, KS--(Marketwired - Feb 6, 2014) - (Family Features) Despite her career as a scrub nurse for general cancer surgeries, a personal diagnosis of cancer still came as a surprise.
"It...
MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent in Korea
31 janv. 2014 08h35 HE
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Jan 31, 2014) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic...
MMRGlobal Adds Japan & South Korea to China in Filing of Cancer Fighting Patent Under Expedited Patent Allowance Program
26 août 2013 08h35 HE
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwired - Aug 26, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic...
Lack of Information Biggest Barrier for Lymphoma Patients
21 déc. 2012 15h54 HE
|
Lymphoma Coalition
Mississauga, Ontario, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Lack of basic, but crucial, information acts as a barrier to the
proper diagnosis and treatment of lymphoma patients worldwide. This
contributes...
MMRGlobal to File Anti-CD20 Antibody and B-Cell Vaccine Patents Targeting Cancers
27 juil. 2012 08h35 HE
|
MMRGlobal, Inc.
LOS ANGELES, CA--(Marketwire - Jul 27, 2012) - MMRGlobal, Inc. (www.mmrglobal.com) (OTCBB: MMRF) ("MMR") today announced that it is filing two additional divisional patent applications that are...